DepoMed, Inc. 

(Public, NASDAQ:DEPO)   Watch this stock   
Find more results for DEPO
Oct 29, 2009
Q3 2009 Depomed Earnings Conference Call - Webcast
Oct 29, 2009
Q3 2009 Depomed Earnings Release
Sep 16, 2009
Depomed at BioCentury `NewsMakers in the Biotech Industry` Clear Route Investment Conference - Webcast
Sep 9, 2009
Depomed at Rodman & Renshaw Annual Global Investment Conference
More events from AOL Finance »    

Key stats and ratios

Q3 (Sep '09) 2008
Net profit margin 5.97% -43.92%
Operating margin 6.15% -49.06%
EBITD margin - -46.19%
Return on average assets 5.72% -17.42%
Return on average equity 33.36% -47.54%
Employees 81 -

Address

1360 O'Brien Drive
Menlo Park, CA 94025
United States - Map
+1-650-4625900 (Phone)
+1-650-4629993 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Options - Morningstar
Research Reports - Yahoo Finance

DepoMed, Inc. discussed on blogs

Ranking All U.S. Stocks by Weekly Performance - NASD100.com ... - Investor's Resources - NASD100.com - Daily Stock Rankings - 17 hours ago
Ranking 1100+ Micro Cap Stocks by Upside Potential - NASD100.com ... - Investor's Resources - NASD100.com - Daily Stock Rankings - Nov 20, 2009

DepoMed, Inc. discussions

  View all discussions »

Description

Depomed, Inc. (Depomed) is a specialty pharmaceutical company focused on the development and commercialization of differentiated products that are based on oral drug delivery technologies. Depomed has developed two commercial products: GLUMETZA (metformin hydrochloride extended release tablets), which is a once-daily treatment for adults with type 2 diabetes that it commercializes in the United States with Santarus, Inc. (Santarus). ProQuin XR (ciprofloxacin hydrochloride extended release tablets), which is a once-daily treatment for uncomplicated urinary tract infections that Depomed commercializes in the United States with Watson Pharma (Watson).

Officers and directors

Craig R. Smith M.D.
Chairman of the Board
Age: 63
Bio & Compensation - Reuters
Carl A. Pelzel
President, Chief Executive Officer, Director
Age: 58
Bio & Compensation - Reuters
Tammy L. Cameron
Vice President - Finance
Age: 43
Bio & Compensation - Reuters
William Callahan
Vice President - Operations
Bio & Compensation - Reuters
Matthew M. Gosling
Vice President, General Counsel
Age: 38
Bio & Compensation - Reuters
Shay Weisbrich
Vice President - Marketing
Bio & Compensation - Reuters
Michael Sweeney M.D.
Vice President - Research & Development
Age: 48
Bio & Compensation - Reuters
G. Steven Burrill
Director
Age: 64
Bio & Compensation - Reuters
Julian N. Stern
Director
Age: 84
Bio & Compensation - Reuters
Peter D. Staple
Director
Age: 57
Bio & Compensation - Reuters